Brief: Proqr Announces Positive Phase 1 Target Engagement Data For Ax-0810, Establishing First Clinical Validation Of The Axiomer Rna Editing Platform
25/06/2026 12:19
BRIEF-Proqr Announces Positive Phase 1 Target Engagement Data For Ax-0810, Establishing First Clinical Validation Of The Axiomer Rna Editing Platform June 25 (Reuters) - ProQR Therapeutics NV PRQR.O:
PROQR ANNOUNCES POSITIVE PHASE 1 TARGET ENGAGEMENT DATA FOR AX-0810, ESTABLISHING FIRST CLINICAL VALIDATION OF THE AXIOMER RNA EDITING PLATFORM
PROQR THERAPEUTICS NV - AX-810 SHOWS FAVORABLE SAFETY PROFILE AND EIGHT-WEEK HALF-LIFE
PROQR THERAPEUTICS NV - AX-2911 FIRST-IN-HUMAN IIT IN CHINA EXPECTED FIRST HALF 2027
PROQR THERAPEUTICS NV - AX-422 CTA FILING FOR MPS1 EXPECTED EARLY 2027 WITH INITIAL DATA FIRST HALF 2027
PROQR THERAPEUTICS NV - PHASE 2 PROGRAM EXPECTED TO START MID-2027 WITH INTERIM DATA BY MID-2028
Source text: ID:nGNX7mH6gl
Further company coverage: PRQR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ProQR Therapeutics NV
See all newsProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary
ProQR Q2 revenue more than doubles
Brief: ProQR Therapeutics Q2 EPS EUR -0.08
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview